Article
Chime Biologics And Daewoong Pharmaceutical Partner On Dupilumab Biosimilar
Chime Biologics and Daewoong Pharmaceutical have formed a strategic partnership to develop and manufacture a dupilumab biosimilar candidate targeting Sanofi and Regeneron's blockbuster DUPIXENT.
Goodwin Procter LLP